Paradoxical High-Density Lipoprotein Reduction Induced by Fenofibrate and Ciprofibrate

Abstract

Keywords

apolipoprotein A apolipoprotein B CK liver dysfunction muscle damage

References

Scandinavian Simvastatin survival study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 334: 1383–9.

Oliver

Poole-Wilson

Shepherd

Tikkanen

Lower patients' cholesterol now. BMJ 1995; 310: 1280–1.

Farnier

Bonnefous

Debbas

Irvine

Comparative efficacy and safety of micronised fenofibrate and simvostatin in patients with primary type IIa or IIb hyperlipidaemia. Arch Intern Med 1994; 154: 441–9.

Hahmann

Bunte

Hellwig

Hau

Becker

Dyckmans

Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy. Am J Cardiol 1991; 67: 957–61.

Chandler

Batchelor

. Ciprofibrate and lipid profile [Letter]. Lancet 1994; 344: 128–9.

McLeod

Warren

Armitage

Ciprofibrate and lipid profile [Letter]. Lancet 1994; 344: 955.

Capps

Lipid profiles on fibric acid derivatives [Letter]. Lancet 1994; 344: 684–5.